Company intelligence / Profile preview

Ai-nova Acquisition Corp

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

No conclusive clinical results yet; the company is preparing for a U.S. pivotal study (FDA pre-submission meeting scheduled July 2025) using its VisionAI solution for early diabetic retinopathy screening in ~1,000 diabetic patients.

Therapeutic areas: NephrologyCardiovascularOphthalmologyEndocrinologyGastroenterologyNeurologyOther
Modalities: DeviceSoftwareArtificial intelligence
Industry: Medical Imaging

Partnerships

Joint venture: Avant Technologies (public company) and Ainnova Tech (privately held healthtech)CRO: Fortrea (patient recruitment/clinical study for diabetic retinopathy, ophthalmology)Grupo Dökka/Fischel/La Bomba pharmacies (Latin America pilot rollouts)

Beyond the preview

Go deeper on Ai-nova Acquisition Corp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ai-nova Acquisition Corp.

Explore the full profile